Characterization of the metabolites of alosetron in experimental animals and human

Xenobiotica

Volumn 35, Issue 2, 2005, Pages 131-154

  Ismail, I M ^a   Andrew, P D ^a   Cholerton, J ^a   Roberts, A D ^a   Dear, G J ^a   Taylor, S ^a   Koch, K M ^b   Saynor, D A ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

5 HT3 antagonists; Alosetron; Irritable bowel syndrome (IBS); Metabolism

Indexed keywords

ALOSETRON; DRUG METABOLITE; GR 153732X; GR 163860X; GR 168355X; GR 168557X; GR 169307X; GR 87620X; GR 96105X; SEROTONIN 3 ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DRUG ISOLATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IRRITABLE COLON; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE; RABBIT; RAT; STRUCTURE ANALYSIS;

ANIMALS; CARBOLINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; DOGS; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; MICE; MODELS, CHEMICAL; RABBITS; RADIOCHEMISTRY; RATS; SEROTONIN ANTAGONISTS; SPECIES SPECIFICITY; TIME FACTORS;

ANIMALIA; CANIS FAMILIARIS; ORYCTOLAGUS CUNICULUS;

EID: 20044378349     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250400028247     Document Type: Article

References (11)

1. Baillie TA, Cayen MN, Hassan F, Gerson RJ, Green JD, Grossman SJ, Klunk LJ, Lebanc B, Perkins DG, Shipley LA. 2002. Metabolites in safety testing. Toxicology and Applied Pharmacology 182:188-196.
2. 3 receptor antagonists in the treatment of irritable bowel syndrome. Aliment Pharmacology 11:3-15.
3. Cremoni F, Delgado-Aros S, Camilleri M. 2003. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomised trials. Neurogastroenterology and Motility 15:79-86.
4. Humphrey PPA, Bountra C, Clayton N, Kozlowski K. 1999. The therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome. Alimentary Pharmacology and Therapy 13:31-38.
5. Knaggs AR, Cable KM, Cannell RJP, Sidebottom PJ, Wells GN, Sutherland DR. 1995. Biotansformation of alosetron: mechanism of hydantoin formation. Tetrahedron Letters 36:477-480.
6. Olden KW. 2002. Diagnosis of irritable bowel syndrome. Gastroenterology 122:1701-1714.
7. Prior A, Read NW. 1993. Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome. Alimentary Pharmacology and Therapy 7: 175-180.
8. Ringel Y, Sperber AD, Drossman DA. 2001. Irritable bowel syndrome. Annual Reviews in Medicine 52:319-338.
9. Saito YA, Schoenfeld P, Locke GR III. 2002. The epidemiology of irritable bowel syndrome in North America: a systematic review. American Journal in Gastroenterology 97:1910-1915.
10. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. 1999. Functional bowel disorders and functional abdominal pain. Gut 45(Suppl. 2):II43-II47.
11. Wolfe S, Chey WY, Washington MK, Harding J, Heath AT, McSorley DJ, Dukes GE, Hunt CM. 2001. Tolerability and safety of alosetron during long term administration in female and male irritable bowel syndrome patients. American Journal of Gastroenterology 96:803-811.